Adding non-invasive prenatal genetic screening (NIPS) for fetal chromosomal abnormalities to the current prenatal testing strategy in Quebec would be more cost-effective than current approaches based on blood tests and amniocentesis, according to research presented at the American Society of Human Genetics (ASHG) 2016 Annual Meeting in Vancouver, B.C.
To learn more about PEGASUS research findings led by Dr. François Rousseau from the CHU de Québec, Université Laval: http://www.ashg.org/press/201610-NIPS-costs.html